Manage Macular Cystoid Edema with Retinal Vein Obstruction Using Traditional Chinese Medicine and Ranibizumab

Launched by DONGYANG PEOPLE'S HOSPITAL · Jan 30, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how well a combination of traditional Chinese medicine (called Jueling Mingmu Decoction) and a medication called ranibizumab can help treat macular cystoid edema, a condition where fluid builds up in the central part of the retina, often due to blocked blood vessels in the eye. The goal is to see if this combination can improve vision and reduce swelling in patients who have been diagnosed with this condition within the last nine months.

To participate in the study, individuals need to be between the ages of 65 and 74 and have specific eye conditions, such as swelling in the retina that affects their central vision. They should not have received any prior treatments for their eye issue. However, those with other serious eye diseases or health conditions that could complicate treatment are not eligible. Participants can expect to receive this combined treatment and be monitored for its effectiveness and safety throughout the study. This trial is currently recruiting new participants, and it's an opportunity to explore a potential new approach to managing this eye condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Foveal center-involved macular edema (ME) lasting less than 9 months
• • Central Macular Thickness (CMT) greater than or equal to 250 μm
• • Best-Corrected Visual Acuity (BCVA) of 24-73 letters (20/40 to 20/320) in the study eye
• • Initial diagnosis with no prior treatments, such as laser therapy or intravitreal injections
• Exclusion Criteria:
• • Presence of any additional macular pathology, such as age-related macular degeneration (AMD) or diabetic retinopathy (DR) affecting the macula
• • Concurrent serious conditions, such as cardiovascular diseases, liver, or kidney diseases
• • Concerns or doubts regarding treatment
• • Known allergies to the ingredients of the medication.

Trial Officials